Management of Pentobarbital-Associated Metabolic Acidosis
Immediately discontinue the pentobarbital infusion when metabolic acidosis develops, as this is most likely propylene glycol toxicity from the 40% propylene glycol vehicle in the formulation. 1, 2
Recognition and Diagnosis
The metabolic acidosis associated with pentobarbital infusion is not caused by pentobarbital itself, but rather by the propylene glycol (PG) vehicle that comprises 40% v/v of the injectable formulation 1. This typically manifests as:
- Anion gap metabolic acidosis
- Elevated serum lactate (from PG metabolism)
- Hyperosmolality with increased osmolal gap
- Onset typically within 12-24 hours of continuous infusion 2
The key diagnostic features distinguishing PG toxicity include the combination of anion gap acidosis with an elevated osmolal gap, which should prompt immediate consideration of this complication 2.
Immediate Management Algorithm
Step 1: Stop the Pentobarbital Infusion
Discontinue pentobarbital immediately upon recognition of metabolic acidosis with elevated osmolal gap 2. The acidosis and hyperosmolality typically resolve after discontinuation, as demonstrated in case reports where complete resolution occurred following drug cessation 2.
Step 2: Supportive Care
- Monitor arterial blood gases serially to track pH, bicarbonate, and PCO2
- Check serum electrolytes, particularly sodium and potassium
- Measure ionized calcium (can decrease with bicarbonate therapy)
- Calculate anion gap and osmolal gap to confirm PG toxicity
- Assess lactate levels (elevated in PG toxicity)
Step 3: Consider Bicarbonate Therapy (Judiciously)
While the primary treatment is drug discontinuation, if severe acidemia (pH < 7.2) persists:
- Use isotonic bicarbonate solutions rather than hypertonic formulations to avoid hypernatremia 3
- Administer slowly with serial monitoring of pH, electrolytes, and ionized calcium
- Adjust mechanical ventilation to increase minute ventilation and eliminate excess CO2, preventing intracellular acidosis 3
- Monitor for complications: hypernatremia, hypokalemia, ionic hypocalcemia, and rebound alkalosis 3
The goal is not to normalize pH completely, but to maintain pH > 7.2 while the underlying cause resolves 4, 3.
Important Clinical Considerations
High Complication Rate
Pentobarbital infusions carry a 62.5% complication rate in pediatric studies, including blood pressure instability (25%), oversedation (12.5%), and drug reactions (12.5%) 5. This underscores the importance of vigilant monitoring.
Extracorporeal Treatment
For severe, refractory cases, hemodialysis or hemoperfusion can be considered 6. However, pentobarbital has:
- High protein binding (35-70%)
- Large volume of distribution (0.5-1.0 L/kg)
- Primarily hepatic metabolism with <5% renal excretion 6
These properties make extracorporeal removal less effective than for long-acting barbiturates like phenobarbital. Hemodialysis clearance for pentobarbital is 8-85 mL/min, compared to 23-174 mL/min for phenobarbital 6.
Common Pitfalls to Avoid
- Do not continue pentobarbital hoping the acidosis will self-resolve—PG accumulates with ongoing infusion
- Do not use hypertonic bicarbonate without careful sodium monitoring—hypernatremia worsens outcomes 3
- Do not aggressively correct pH to normal—target pH > 7.2 is sufficient and reduces complications 4, 3
- Do not forget to increase ventilation when giving bicarbonate to mechanically ventilated patients—failure to eliminate CO2 causes intracellular acidosis 3
- Do not overlook ionized calcium monitoring—bicarbonate therapy can precipitate symptomatic hypocalcemia requiring calcium supplementation 3
Alternative Sedation Strategy
Once pentobarbital is discontinued, transition to alternative sedation that does not contain propylene glycol. The original indication for pentobarbital (typically refractory status epilepticus or severe agitation) will need to be managed with other agents or combinations thereof.